CUMBERLAND PHARMACEUTICALS INC — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Cumberland Pharmaceuticals completed sale of FDA-approved branded business to Apotex Health (largest Canadian pharmaceutical company) for $100M cash plus $11M for inventory/transition, closing July 1, 2026. Board approved special dividend of $1.50/share paid July 31, 2026 to ~15M shares outstanding (~$22.5M total). Company retains development pipeline (four Phase 2 programs including ifetroban) and majority stake in Cumberland Emerging Technologies; transitions to development-stage focus. Transaction approved by >99% shareholder vote.
Why this rating
Sale of primary revenue-generating business (~$4.3B valuation impact) plus $22.5M dividend return (77% of market cap) fundamentally transforms company. Positive: strengthens balance sheet, returns capital, funds R&D runway. Negative: eliminates commercial revenue stream. Material relative to $29.4M market cap.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.